Market Analysis - (2019) Volume 5, Issue 3
Market Analysis for Biomarker Congress 2020
The market for biomarker technologies is assigned to reach USD 74.51 billion for 2022 from USD 46.97 billion in 2017, at a compound annual rate of 9.7% during the expected time frame.
Dependent on the type of product, the market for biomarker technologies is separated into devices, amenities information technology. In 2018, the consumables part depended on to signify the largest market share due to its higher sales volume compared to the instruments. The consumables marketplace is further disjointed into kits, reagents and chromatography columns. In 2018, the sets and reagents segments denoted the largest in the consumables market.
By disease, the biomarkers market comprises immunological diseases, cancer, neurological diseases, cardiovascular diseases, and others. The cancer segment dominates the global biomarkers market, due to the growing demand for accurate and rapid diagnostic tools and rising cancer incidences globally. According to the National Cancer Institute, about 268,670 new cases of breast cancer were recorded in 2018 in the U.S.
Although critical improvements have been made in the area of biomarkers, deducing them priceless clinical trials is dejected and a major problem to the clinical use of these biomarkers. The advance of this market is obsessed by factors such as the growth of health spending, the increase in R & D funding, and the increase in the usefulness of biomarkers for investigative purposes and the growth in the research of biomarkers.
In 2017, North America signified the major share in the biomarker market. The Asia Pacific verified the highest growth from 2017 to 2022 for the biomarker advances to market. Factors such as the growing rate of malignancy, the development of the geriatric population and the support of private and public links for biomarker research are driving the development of this regional section. By influencing advance, the biomarker breakthrough market is categorized by immunoassays, PCR, mass spectrometry, NGS, chromatography, cytogenetic and other different advances. The immunoassay percentage accounted for most of it in 2017. This section is additionally categorized into ELISA, western blot and protein microarrays. In 2017, the ELISA fragment exemplified the major share in the immunoassay market.
In the upcoming years, the Asia Pacific region is expected to record high growth in the global biomarker industry.The rising incidence of chronic diseases such as neurological disorders, cancer and cardiovascular diseases, increased regional government support for drug discovery and development programs, increased awareness of disease diagnosis among biomarkers and a large pool of patients are the main factors that boost the development of the biomarkers market.
China, Japan, and India are expected to be major contributors to the Asia Pacific biomarkers market in the future. The favorable environment for clinical trials in the Asia Pacific is likely to fuel the biomarkers market over the forecast period.
Market Analysis of Biomarkers by Region
This report analyzes emerging markets in the disease segment. Endless growth is estimated in emerging geographies, driven by the growing middle class in emerging countries like India, China, Brazil, and Russia. It is important to stress that the ability to integrate an effective strategy begins with the place where the opportunity exists and ends with the way in which it can be effectively implemented in order to reap the benefits of the opportunity.
Scope & Importance:
The biomarker market presents the highest of all prospects in sub-segments of representative diseases. This study examines one of the most important engines of the market: the overview of combination analyses, which are estimated to continue contributing significantly to market development during the forecast period. This report studies emerging markets by disease segment. Endless growth is estimated in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia. This report seeks to address issues of critical importance to analyze a changing market dynamics, emerging players and machinery, approaches to access emerging markets and specific disease segments and geographies to allocate resources and make operative decisions. For companies with an actual approach, the market opportunity expects you. It is important to emphasize that the ability to develop an effective strategy begins with the place where the opportunity exists and ends with the way to execute effectively to obtain the opportunity's profits.
2nd International Conference on Biomarkers and Cell Biology
June 15-16, 2020Dubai, UAE
